NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free AUTL Stock Alerts $4.56 +0.04 (+0.88%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$4.48▼$4.6550-Day Range$4.52▼$7.2552-Week Range$1.61▼$7.45Volume1.15 million shsAverage Volume1.50 million shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$8.16 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Autolus Therapeutics alerts: Email Address Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside78.9% Upside$8.16 Price TargetShort InterestHealthy1.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector394th out of 909 stocksBiological Products, Except Diagnostic Industry55th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.57% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 32.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.5 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesApril 21, 2024 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%April 21, 2024 | nasdaq.comRSI Alert: Autolus Therapeutics (AUTL) Now OversoldApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 20, 2024 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 3.7%April 19, 2024 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.86April 14, 2024 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Autolus Therapeutics (NASDAQ:AUTL)April 12, 2024 | markets.businessinsider.comBuy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive OutlookApril 9, 2024 | investing.comTruist raises Autolus Therapeutics stock target on market lead potentialApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 2, 2024 | finance.yahoo.comAutolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)April 1, 2024 | globenewswire.comAutolus Therapeutics Announces Changes to its Board of DirectorsMarch 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday TradingMarch 18, 2024 | markets.businessinsider.comBreaking Down Autolus Therapeutics: 4 Analysts Share Their ViewsMarch 17, 2024 | finance.yahoo.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-celMarch 15, 2024 | finance.yahoo.comQ4 2023 Autolus Therapeutics PLC Earnings CallMarch 15, 2024 | finance.yahoo.comAutolus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 15, 2024 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 15, 2024 | msn.comAutolus Therapeutics FY 2023 Earnings PreviewMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)March 14, 2024 | finance.yahoo.comAutolus Therapeutics PLC Reports Full Year 2023 Financial ResultsMarch 14, 2024 | seekingalpha.comAutolus Therapeutics plc 2023 Q4 - Results - Earnings Call PresentationMarch 14, 2024 | msn.comAutolus Therapeutics GAAP EPS of -$1.20 misses by $0.10, revenue of $1.69M misses by $0.01MMarch 14, 2024 | globenewswire.comAutolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 13, 2024 | benzinga.comAutolus Therapeutics's Earnings OutlookMarch 12, 2024 | globenewswire.comAutolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteMarch 11, 2024 | finance.yahoo.comAutolus Therapeutics announces publication in Blood Cancer JournalSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/22/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees463Year FoundedN/APrice Target and Rating Average Stock Price Target$8.16 High Stock Price Target$11.00 Low Stock Price Target$4.80 Potential Upside/Downside+78.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-208,380,000.00 Net MarginsN/A Pretax Margin-12,273.38% Return on Equity-105.75% Return on Assets-49.25% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio6.15 Sales & Book Value Annual Sales$1.70 million Price / Sales713.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book7.13Miscellaneous Outstanding Shares265,930,000Free Float197,583,000Market Cap$1.21 billion OptionableOptionable Beta1.90 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 60)CEO & Director Comp: $2.39MDr. Martin Pule M.D. (Age 52)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Robert F. Dolski (Age 53)Senior VP & CFO Mr. Christopher Vann (Age 59)Senior VP & COO Mr. David Brochu (Age 68)Senior VP & Chief Technical Officer Mr. Alexander Swan (Age 59)Senior VP & Chief Human Resources Officer Mr. Brent Rice (Age 58)Senior VP, Chief Commercial Officer & Site Head of US Ms. Olivia ManserDirector of Investor RelationsMr. Alex DriggsSenior VP of Legal Affairs & General Counsel and SecretaryDr. Chris Williams (Age 44)Senior VP & Chief Business Development Officer More ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTTarsus PharmaceuticalsNASDAQ:TARSADMA BiologicsNASDAQ:ADMAVir BiotechnologyNASDAQ:VIRScholar RockNASDAQ:SRRKView All CompetitorsInstitutional OwnershipPerpetual LtdBought 169,784 shares on 4/10/2024Ownership: 0.840%Perceptive Advisors LLCBought 1,831,167 shares on 2/26/2024Ownership: 1.053%Sierra Summit Advisors LLCBought 42,744 shares on 2/22/2024Ownership: 0.025%TFG Asset Management GP LtdSold 4,000,000 shares on 2/14/2024Ownership: 4.599%Bellevue Group AGBought 50,000 shares on 2/14/2024Ownership: 0.029%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price target for 2024? 5 brokerages have issued 12 month price objectives for Autolus Therapeutics' stock. Their AUTL share price targets range from $4.80 to $11.00. On average, they expect the company's share price to reach $8.16 in the next year. This suggests a possible upside of 78.9% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2024? Autolus Therapeutics' stock was trading at $6.44 at the beginning of the year. Since then, AUTL stock has decreased by 29.2% and is now trading at $4.56. View the best growth stocks for 2024 here. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) issued its earnings results on Thursday, March, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. What ETF holds Autolus Therapeutics' stock? Harbor Disruptive Innovation ETF holds 93,201 shares of AUTL stock, representing 1.50% of its portfolio. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perpetual Ltd (0.84%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUTL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyIncredible Opportunity to Retire FAST!Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
